Replies to post #241315 on Biotech Values

[DewDiligence]

More from PRDS S-1 filing (p.97):

All employees currently work remotely. We intend to lease office space and labs in mid-2022.

[DewDiligence]

(ENTA/PRDS/etc)—SRNE says its SARS-CoV-2 protease inhibitor won’t need ritonavir boosting:

https://www.globenewswire.com/news-release/2022/01/28/2375086/0/en/Sorrento-Announces-Its-Oral-SARS-CoV-2-Main-Protease-Mpro-Inhibitor-STI-1558-Strongly-Neutralizes-Omicron.html

SRNE could be a serious competitor. On the other hand, SRNE has a history of making big claims.